Mechanisms for Activation of Beige Adipose Tissue in Humans
ConditionPreDiabetes
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age35-65
SponsorPhilip Kern
About this trial
Mirabegron (Myrbetriq®, Astellas) is a highly specific and well-tolerated ß3 agonist marketed for overactive bladder. This trial will assess the effects of mirabegron on glucose tolerance and adipose tissue in prediabetic patients
Eligibility criteria
Qualifiers
BMI 27-45
prediabetes (A1c 5.7-6.4)
impaired fasting glucose or impaired glucose tolerance
Disqualifiers
diabetes
chronic use of anti-diabetic medication
acute or chronic inflammatory condition
unstable medical condition
Trial design
Treatments tested in this trial
- Placebo
- Mirabegron
- Mirabegron 50 MG
- Mirabegron 100 mg
Treatment groups
65 Participants
are divided into 4 treatment groupsSponsors and collaborators
Philip Kern
Lead sponsor
University of Kentucky
Sponsor institution
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborator
Source ClinicalTrials.gov